GERMANTOWN, Md., June 4, 2025 — Senseonics Holdings, Inc. (NYSE American: SENS), a leader in medical technology, has announced plans to host an in-person and virtual analyst event at the American Diabetes Association’s 85th Scientific Sessions (ADA 2025) on Saturday, June 21, 2025, at 8:00 AM CT. The event will be held at the Marriott Marquis Chicago. Interested parties can register here.
The event will feature insights from the company’s management team, who will present the next-generation Eversense® 365 Continuous Glucose Monitoring (CGM) system. The system, recently approved by the U.S. Food and Drug Administration (FDA), is designed for people aged 18 and older with diabetes.
Alongside company leaders, the event will include presentations from Brian Hansen of Ascencia Diabetes Care, who will discuss the commercial launch of Eversense 365. Gary Graf, MSN, APRN-C, from the Cotton-O’Neil Diabetes and Endocrinology Center, will share his experience with the Eversense system and its insertion procedure. The session will also highlight Senseonics’ recent partnership with Sequel to integrate the Eversense 365 system with the Twiist automated insulin delivery pump, and plans to expand its pipeline of implantable CGM technologies.
A live question-and-answer session will follow the formal presentations.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company specializing in long-term implantable glucose monitoring systems. Its products, including the Eversense® 365 and Eversense® E3 CGM systems, feature a small sensor inserted under the skin, transmitting glucose data every five minutes to a mobile app. The company’s goal is to improve the lives of people with diabetes globally through innovative, long-term glucose management technology.
Related Topics
